Clinical Trial Search

Primary: Number of Participants With First Occurrence of Any Component of Composite MACE (CV Death, MI, or Stroke) — 439; 472 Participants — p=0.121

Primary: Severity of Side Effects Reported at End of Stimulation Session as Reported by the Participant on the Stimulation Side Effects Questionnaire. — 5.66; 5.00 score on a…

Primary: Insulin Sensitivity — 6.82 mg/kg FFM/min

Primary: Percentage of Participants Who Experience One or More Treatment-related Adverse Events (AEs) — 14.3; 29.4 Percentage of participants

Primary: Percentage of Participants Achieving Best Overall Response of Complete Response (CR), as Assessed by the Independent Review Committee (IRC) — 83.3 percentage of…

Primary: Percentage of Patients Who Were Ready to Make a Decision or Were Undecided — 134; 90; 144; 125 Participants

Primary: GBS Culture Result (Positive Versus Negative) — 3; 6; 18; 19 Participants

Primary: Weight — 107.6; 105.1; 109.7; 106.7 Kilogram — p=<0.01

Primary: Comparison of Overall Survival (OS) Between the Active Treatment Group (Arms 1 and 2) and the Control Group (Arm 3) — 16.9; 16.2; 20.6 months — p=0.196

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants

Primary: Difference in Adenomas Per Colonoscopy (APC) — 0.60; 0.74 Resected adenomas — p=0.0002

Primary: Efficacy of Lifitegrast Ophthalmic Solution 5% in Treating the Symptoms of Dry Eye in Contact Lens Wearers as Measured by Change in Total CLDEQ-8 Score From Baseline to…

Primary: Change in EDS (VAS) From Baseline to Day 85 — -18.0; -19.4 mm — p=0.5019

Primary: Percentage of Correct Answers by Participants on Questions Designed to Evaluate Attitudes Towards Antimicrobial Resistance (Sentiment) — 81; 83.2; 86.3; 85.2 percentage…

Primary: Number of Participants With Treatment-Emergent Adverse Events — 34; 31; 30; 11 participants